NovoCure Reports First Quarter 2016 Financial Results And Provides Company Update

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported financial results for the first quarter ended March 31, 2016, highlighting strong growth in prescriptions, active patients and reported revenues.
MORE ON THIS TOPIC